Building up on our preclinical data, which showed an impact of OCTN2 expression on GBM patient survival and a significant growth-reduction using the OCTN2 inhibitor meldonium in an orthotopic GBM mouse model [12], we report here the experimental use of meldonium in patients with recurrent end-stage GBM. The gene discussed is SLC22A5; the disease is glioblastoma.